Xellar Biosystems

Xellar Biosystems, founded in 2019 and based in Boston, is developing an innovative organ-on-chip platform combined with artificial intelligence to improve the predictive accuracy of preclinical drug testing. The company's E.P.I.C. Platform (Engineering, Preclinical, Imaging, Computation) creates a closed-loop feedback system for scalable exploration of human biology, aiming to address critical limitations of 2D cultures, 3D organoids, and animal models. By providing physiologically realistic human organ models, Xellar seeks to de-risk drug development, shorten timelines, and promote regulatory adoption of human-relevant testing methods.

E.P.I.C. Platform: An integrated closed-loop system combining Engineering (high-throughput, barrierless organ-on-chip devices), Preclinical (multicellular 3D disease models on-chip), Imaging (high-content 3D imaging), and Computation (AI/ML for multiplexed image and data analysis) to create predictive human biology models for drug discovery.

Xellar competes in the organ-on-chip and complex in vitro model market against companies like Emulate, Mimetas, and CN Bio, as well as 3D organoid specialists. Its claimed differentiation is a focus on 'pharma-scale' high-throughput screening combined with a proprietary, integrated image-based AI analytics platform.